Accelerating enrollment faster than expected in cardiovascular trials
From hypertension and strokes to coronary artery disease, patients can experience a myriad of challenges. And that means patient recruitment in this therapeutic area requires a unique understanding of the patient journey, combined with a strategy built in precision and trust.
1nHealth takes full ownership of the enrollment process across this wide-ranging therapeutic area—making patient recruitment one less challenge for your next study.
From a recent cardiovascular trial:
0
%
Qualification rate on all submissions
0
Days saved on enrollment timeline
0
Patients enrolled in two weeks
Our difference
Clinical trials are at the heart of cardiovascular treatment innovation
Cardiovascular diseases affect 523 million individuals worldwide and is a leading cause of death globally.
Cardiovascular clinical trials are complex and competitive. Engaging and retaining vulnerable patient populations can be challenging.
At 1nHealth, we own the enrollment process and remove those roadblocks so that you can focus on delivering results that push modern medicine forward.
For clinical trial sponsors who refuse to settle for enrollment delays and inefficiencies, we reset the standard
- You need a recruitment partner who understands how every step of the funnel works together to deliver results on time and under budget
- You rely on experts who understand complex I/E criteria to ensure patient populations are wide-reaching and qualified upon referral
- You demand consistent performance and high-touch patient engagement on lengthy trials that often enroll elderly populations
- You expect quick and efficient site support when trials are enrolling extremely large patient populations globally
Our expertise
Coronary Heart Disease
Coronary heart disease (CHD), a leading global cause of morbidity and mortality, affects an estimated 126 million people worldwide, with prevalence increasing in aging populations.
Risk factors such as hypertension, hyperlipidemia, diabetes, smoking, and genetic predisposition contribute to disease progression, with significant ethnic disparities observed—African Americans and South Asians face heightened risks. Symptoms include angina, dyspnea, and fatigue.
Hypertension
Hypertension, or high blood pressure, affects over 1.3 billion people globally and is a leading modifiable risk factor for cardiovascular disease, stroke, and kidney failure.
Often termed the “silent killer,” hypertension is frequently asymptomatic until complications arise.
Stroke
Strokes are a leading cause of death and disability worldwide, affecting 12.2 million people annually, with ischemic strokes accounting for 87% of cases.
Lifestyle factors, such as smoking and poor diet, and socioeconomic disparities further contribute to stroke risk. Symptoms include sudden weakness, speech difficulties, and loss of coordination, emphasizing the need for rapid intervention.
Our success
"1nHealth's expertise and close collaboration was a key factor to the success of our study. They were able to adapt to some unexpected challenges and provided valuable insight."
Sponsor
Breast Cancer Chemo Fatigue
Hover to reveal top creative
COVID-19 Registry
Hover to reveal top creative
Our experience across other therapeutic areas
Your next trial is thoughtful, complex, and different. Your patient recruitment should be too.
From kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through proven recruitment programs and high-touch patient engagement.
Click each area to learn more.
